NCT00633789 - Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types | Biotech Hunter

Enrollment

597

Participants

Timeline

Start Date

June 30, 2008

Primary Completion Date

February 29, 2012

Study Completion Date

December 31, 2012

Conditions

Advanced Non-small Cell Lung CancerTransitional Cell CarcinomaSoft Tissue SarcomaGastric/Esophageal AdenocarcinomaPancreatic Cancer Including Ampulla of Vater

Interventions

DRUG

brivanib

Tablets, Oral, 800 mg, once daily, until progression

DRUG

Placebo

Tablets, Oral, 0 mg, once daily, until progression

Trial Locations (25)

1000

Local Institution, Brussels

1090

Local Institution, Brussels

1200

Local Institution, Brussels

1264

Local Institution, Capital Federal

1425

Local Institution, Capital Federal

1426

Local Institution, Capital Federal

1650

Local Institution, Buenos Aires

10065

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Cancer Ctr, New York

19104

University Of Pennsylvania, Philadelphia

21231

Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore

60201

Northshore Univ. Healthsystem, Evanston

60637

University Of Chicago, Chicago

75651

Local Institution, Paris

75908

Local Institution, Paris

79106

Local Institution, Freiburg im Breisgau

T6G 1Z2

Local Institution, Edmonton

M5G 2M9

Local Institution, Toronto

06120

Local Institution, Halle

6202 AZ

Local Institution, Maastricht

3075 EA

Local Institution, Rotterdam

3508 GA

Local Institution, Utrecht

80-952

Local Institution, Gdansk

GN11 6NT

Local Institution, Glasgow, Scotland

SM2 5PT

Local Institution, Surrey